{"id":"licensed-influenza-vaccine-2","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Live vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Interferons","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Immunosuppressive drugs","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Antiviral drugs","action":"Monitor","effect":"Unknown"},{"drug":"Corticosteroids","action":"Monitor","effect":"Unknown"},{"drug":"Immunoglobulins","action":"Monitor","effect":"Unknown"},{"drug":"Blood products","action":"Monitor","effect":"Unknown"}],"commonSideEffects":[],"contraindications":["History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (other than egg), or to a previous dose of any influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of any valency)","History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine","Moderate or severe acute illness with or without fever","History of severe allergic reaction (e.g., anaphylaxis) to RIV of any valency, or to any component of RIV3","Receipt of influenza antiviral medication within the previous 48 hours for oseltamivir and zanamivir, 5 days for peramivir, and 17 days for baloxavir","Persons with cochlear implants (due to potential for CSF leak, which might exist for some period after implantation","Persons with active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, or ear","Pregnancy","Close contacts and caregivers of severely immunosuppressed persons who require a protected environment","Children and adults who are immunocompromised due"],"specialPopulations":{"Pregnancy":"Pregnant people or those who might become pregnant during the influenza season are especially vulnerable to influenza-related morbidity and mortality. Vaccination is the most effective method for preventing influenza infection and its related complications. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) and other organizations recommend that pregnant people receive the seasonal influenza vaccine.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"BioNTech","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Licensed Influenza Vaccine 2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:41:00.399392+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:41:06.285910+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:41:00.470471+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Licensed Influenza Vaccine 2","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:41:06.643917+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:07.765732+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"Licensed Influenza Vaccine 2 from BioNTech SE is a marketed vaccine for influenza prevention and protection in adults and children 6 years and older. It has generated significant revenue of $3.42 billion. The vaccine has undergone 83 trials and has 5 publications. Its mechanism is not specified on Wikipedia. The vaccine's clinical differentiation and commercial significance are not well-documented. BioNTech SE is a well-established company in the pharmaceutical industry.","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Vaccine","drugClass":"Vaccine","explanation":"","oneSentence":"","technicalDetail":"The mechanism of Licensed Influenza Vaccine 2 is not specified, making it difficult for healthcare professionals to understand its pharmacological properties and potential interactions with other medications."},"_companyIR":{"url":"https://www.biontech.com/ir","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"+2.4%","annualCostUS":"80,000","genericStatus":"Generic — off-patent","currentRevenue":"3,420,004,257","peakSalesEstimate":"21.2B"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Licensed Influenza Vaccine 2","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Licensed%20Influenza%20Vaccine%202","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Licensed Influenza Vaccine 2","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:09.396858+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Tamiflu (oseltamivir)","company":"Roche","advantage":"Antiviral medicine used for the treatment or prevention of the flu"},{"name":"Xofluza (baloxavir marboxil)","company":"Genentech","advantage":"Used for the treatment and post-exposure prophylaxis of influenza"},{"name":"Fluzone","company":"Sanofi Pasteur","advantage":"Used for influenza prophylaxis"},{"name":"Afluria","company":"Seqirus","advantage":"Vaccine used to prevent infection caused by influenza virus"},{"name":"Fluad","company":"Seqirus","advantage":"Used to prevent influenza"},{"name":"Flucelvax Quadrivalent","company":"Novartis","advantage":"Inactivated influenza virus vaccine used for the prevention of influenza"},{"name":"Flublok","company":"Sanofi Pasteur","advantage":"Used for influenza prophylaxis"}],"genericName":"licensed influenza vaccine 2","indications":{"approved":[{"name":"Influenza prevention","regulator":"FDA"},{"name":"Influenza protection","regulator":"FDA"},{"name":"Influenza prevention for adults and children 6 years and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT04901455","phase":"EARLY_PHASE1","title":"Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-03","conditions":"COPD","enrollment":24},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT06501963","phase":"PHASE4","title":"Revealing Protective Immunity to Influenza Using Systems Immunology","status":"COMPLETED","sponsor":"Emory University","startDate":"2024-10-14","conditions":"Influenza","enrollment":51},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06680375","phase":"PHASE1","title":"A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"COVID-19","enrollment":106},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT01006798","phase":"PHASE1","title":"Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-10","conditions":"Bird Flu, Influenza","enrollment":166},{"nctId":"NCT04956575","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-06","conditions":"Seasonal Influenza","enrollment":885},{"nctId":"NCT02485639","phase":"PHASE4","title":"Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-23","conditions":"Influenza, Influenza Immunisation","enrollment":27},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT04523090","phase":"PHASE2, PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":"COVID-19","enrollment":322},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT04848467","phase":"PHASE3","title":"COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2021-10-01","conditions":"SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)","enrollment":0},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT03101462","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2011-02-24","conditions":"Influenza","enrollment":38},{"nctId":"NCT02914275","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-27","conditions":"Influenza, Human","enrollment":2250},{"nctId":"NCT01609998","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Influenza","enrollment":75},{"nctId":"NCT03300362","phase":"PHASE2","title":"Improved Novel VaccIne CombinaTion InflUenza Study","status":"TERMINATED","sponsor":"Barinthus Biotherapeutics","startDate":"2017-10-13","conditions":"Influenza","enrollment":862},{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390},{"nctId":"NCT00764790","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Influenza","enrollment":3317},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT02035696","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-12","conditions":"Influenza","enrollment":671},{"nctId":"NCT00374842","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-03","conditions":"Influenza","enrollment":300},{"nctId":"NCT02207413","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-18","conditions":"Influenza","enrollment":1886},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792},{"nctId":"NCT00322049","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Dengue","enrollment":51},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":9003},{"nctId":"NCT01052480","phase":"PHASE2","title":"Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-12","conditions":"Influenza A, Influenza B","enrollment":98},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT00264576","phase":"PHASE2","title":"Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-10","conditions":"Influenza Disease; Flu","enrollment":613},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT00620815","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Influenza","enrollment":601},{"nctId":"NCT01992107","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2333},{"nctId":"NCT02212106","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-09","conditions":"Influenza, Human","enrollment":402},{"nctId":"NCT00424086","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-01","conditions":"Influenza","enrollment":1000},{"nctId":"NCT00976469","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-09","conditions":"Influenza, Pandemic Influenza","enrollment":400},{"nctId":"NCT01240746","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":4363},{"nctId":"NCT01000584","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"David Scheifele","startDate":"2009-11","conditions":"Influenza, H1N1 2009 Influenza","enrollment":309},{"nctId":"NCT01346592","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Influenza Disease","enrollment":6104},{"nctId":"NCT01181323","phase":"PHASE2","title":"Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Influenza","enrollment":240},{"nctId":"NCT01173211","phase":"PHASE2","title":"2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Influenza","enrollment":183},{"nctId":"NCT01162122","phase":"PHASE3","title":"Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-08","conditions":"Influenza","enrollment":7109},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT01657929","phase":"PHASE1","title":"H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Access to Advanced Health Institute (AAHI)","startDate":"2012-09","conditions":"Influenza A Subtype H5N1 Infection","enrollment":105},{"nctId":"NCT01218646","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":739},{"nctId":"NCT01732198","phase":"PHASE2","title":"A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2013-03","conditions":"Infectious Disease","enrollment":220},{"nctId":"NCT01893177","phase":"PHASE3","title":"Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2013-07","conditions":"Influenza","enrollment":110},{"nctId":"NCT00992719","phase":"PHASE2","title":"Novartis H1N1 Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"Influenza","enrollment":84},{"nctId":"NCT00943202","phase":"PHASE2","title":"Sanofi Pasteur, TIV + H1N1, Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":531},{"nctId":"NCT00845429","phase":"PHASE2","title":"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Orthomyxoviruses, Myxovirus Infection","enrollment":729},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":0},{"nctId":"NCT00943878","phase":"PHASE2","title":"Sanofi H1N1 + TIV - Adults and Elderly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":805},{"nctId":"NCT00992433","phase":"PHASE2","title":"H1N1 Vaccine at Two Dose Levels in HIV Positive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"Influenza","enrollment":192},{"nctId":"NCT00231907","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Influenza","enrollment":56}],"_emaApprovals":[{"date":"","name":"Licensed Influenza Vaccine 2","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Shenzhen Lantern Scicence Co.,Ltd.","location":"","operator":"Shenzhen Lantern Scicence Co.,Ltd."}],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Shenzhen Lantern Scicence Co.,Ltd.","relationship":"Originator"}],"publicationCount":5,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Aug 1","pmid":"37257121","title":"Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.","journal":"The Pediatric infectious disease journal"},{"date":"2017 Nov","pmid":"28719500","title":"A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.","journal":"The Pediatric infectious disease journal"},{"date":"2017 May 31","pmid":"28483200","title":"A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.","journal":"Vaccine"},{"date":"2007 Mar","pmid":"17484218","title":"Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.","journal":"The Pediatric infectious disease journal"},{"date":"1995 Nov","pmid":"8584366","title":"Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up.","journal":"The Pediatric infectious disease journal"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Licensed Influenza Vaccine 2","companyName":"BioNTech","companyId":"biontech","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:09.396858+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}